A share price of Arrowhead Pharmaceuticals Inc. [ARWR] is currently trading at $35.11, down -2.69%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ARWR shares have gain 15.15% over the last week, with a monthly amount glided 9.07%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 4, March 2024, Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences. In a post published today on Yahoo Finance, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:.
From an analyst’s perspective:
Arrowhead Pharmaceuticals Inc. [NASDAQ: ARWR] stock has seen the most recent analyst activity on December 04, 2023, when BofA Securities initiated its Buy rating and assigned the stock a price target of $29. Previously, Citigroup started tracking the stock with Neutral rating on September 19, 2023, and set its price target to $33. On July 21, 2023, TD Cowen initiated with a Outperform rating. SVB Securities downgraded its rating to a Market Perform but stick to its price target of $40 on May 12, 2023. SMBC Nikko initiated its recommendation with a Outperform and recommended $80 as its price target on April 26, 2023. SVB Securities upgraded its rating to Outperform for this stock on April 12, 2023, and upped its price target to $35. In a note dated March 21, 2023, Bernstein initiated an Mkt Perform rating and provided a target price of $27 on this stock.
Arrowhead Pharmaceuticals Inc. experienced fluctuations in its stock price throughout the past year between $20.67 and $42.48. Currently, Wall Street analysts expect the stock to reach $63.86 within the next 12 months. Arrowhead Pharmaceuticals Inc. [NASDAQ: ARWR] shares were valued at $35.11 at the most recent close of the market. An investor can expect a potential return of 81.89% based on the average ARWR price forecast.
Analyzing the ARWR fundamentals
Trailing Twelve Months sales for Arrowhead Pharmaceuticals Inc. [NASDAQ:ARWR] were 181.74M which represents -94.32% decline. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -1.65%, Pretax Profit Margin comes in at -1.67%, and Net Profit Margin reading is -1.63%. To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -0.95 and Total Capital is -0.53. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.74.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 34.32 points at the first support level, and at 33.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 36.31, and for the 2nd resistance point, it is at 37.51.
Arrowhead Pharmaceuticals Inc. [ARWR] reported earnings per share of -$1.24 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.82/share, meaning a difference of -$0.42 and a surprise factor of -51.20%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.02 per share as compared to estimates of -$0.6 per share, a difference of -$0.42 representing a surprise of -70.00%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Arrowhead Pharmaceuticals Inc. [NASDAQ:ARWR] is 3.73. Also, the Quick Ratio is 3.73, while the Cash Ratio stands at 0.91. Considering the valuation of this stock, the price to sales ratio is 23.94, the price to book ratio is 23.53.
Transactions by insiders
Recent insider trading involved Anzalone Christopher Richard, Chief Executive Officer, that happened on Jan 31 when 57499.0 shares were sold. Chief Discovery/Trans Medicine, Hamilton James C completed a deal on Jan 12 to sell 7940.0 shares. Meanwhile, Director Vakiener Victoria sold 4720.0 shares on Jan 11.
